BCL2 and B-cell non-Hodgkin lymphoma: Bcl2 has long been associated with drug resistance since its discovery as a proto-oncogene in non-Hodgkin's B-cell lymphomas [29], and over the years, it has been extensively studied as a potential target for cancer therapy [30].